Chief Science Officer and Head of R&D · NovoCure Ltd (NVCR)

Eilon Kirson

A named executive officer of NovoCure in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$3,142,804

Salary $461,783Stock awards $440,618

FY2017: $2,842,591

4th of 6 named executive officers at NovoCure by FY2018 total.

6 named officers on file for NovoCure, FY2018

Eilon Kirson’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • NVCR’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NovoCure’s whole pay program stands against its peers

  • NovoCure’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2019 (DEF 14A).

Free

Get Eilon Kirson’s full pay file as a PDF — free

More than this page: up to 10 years of Eilon’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Eilon Kirson compensation by year

NovoCure Summary Compensation Table · all 3 fiscal years held
In US dollars, as NovoCure reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$419,570$455,284$461,783
Bonus$0$0$0
Stock awards$0$780,780$440,618
Option awards$489,520$1,116,133$1,769,541
Non-equity incentive$0$286,075$286,340
Pension and deferred compensation$0$0$0
All other$128,639$204,319$184,522
Total$1,037,729$2,842,591$3,142,804

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 10, 2019, accession 0001564590-19-011243, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NovoCure Ltd filed document, accession 0001564590-19-011243. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2019.

$1.0M
$2.8M
$3.1M
FY16
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
PSU72,799$2,437,311—
PSU20,833$697,489—
Option152,068—$21.15
Option204,750—$7.15
Option37,500—$11.46
Option66,522—$14.37

Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

NovoCure’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Asaf DanzigerChief Executive Officer$4,570,294
William DoyleExecutive Chairman$4,558,655
Wilhelmus GroenhuysenChief Financial Officer$3,459,217
Eilon Kirson · this pageChief Science Officer and Head of R&D$3,142,804
Pritesh ShahChief Commercial Officer$3,070,496
Michael AmbrogiChief Operating Officer$2,611,707

The full NovoCure compensation record

free company brief

This page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NovoCure proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Eilon Kirson's compensation dossier · One-time report. No refunds.